Single-Dose Phase 0 Exploratory Pharmacokinetic Clinical Trial Comparing Five Oral Formulations of SR13668, an Orally Active AKT Pathway Inhibitor.
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2013
At a glance
- Drugs SR 13668 (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 15 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 15 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.